Project Grant R41CA232867

This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research program) provides $670,534 to Northwestern University to develop an innovative optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer (CRC) risk stratification. The goal is to create an accurate, low-cost screening test that can identify patients with advanced adenomas who would benefit from colonoscopy, thereby increasing CRC screening uptake. The...

The National Cancer Institute (NCI) awarded a $1,403,822 Project Grant (CFDA 93.393 Cancer Cause and Prevention Research) to the University of Chicago to conduct a multi-center, prospective clinical trial examining the performance of the Fecal Immunochemical Test (FIT) in Lynch Syndrome (LS) patients undergoing colorectal cancer surveillance colonoscopies. The study aims to measure FIT test characteristics, evaluate personalized surveillance strategies integrating non-invasive tests and...

This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $697,198 to the University of California, San Diego (UCSD) to develop a targeted colorectal cancer (CRC) screening strategy for adults aged 45-49. The study aims to: 1) characterize the acceptability of CRC screening in this age group and identify factors influencing screening uptake; and 2) conduct a randomized controlled trial to compare...

This $692,491 Cooperative Agreement awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a minimally-invasive blood test for early detection of common cancers, including prostate, lung, colorectal, and ovarian cancer. The project will leverage the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial biospecimens to train and validate individual cancer detection models, develop a multi-cancer...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), will support the development and clinical validation of an Optical Coherence Tomography (OCT) system and two specialized OCT imaging probes to enhance colorectal cancer screening. The $1,471,777 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) aims to create an OCT system that can obtain 3D microscopic images of...

The National Cancer Institute (NCI) awarded a $447,686 Cooperative Agreement under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program to the Alaska Native Tribal Health Consortium (ANTHC) and its partner Fred Hutchinson Cancer Center. The goal of this 5-year project is to establish the first community-engaged cohort study to investigate risk factors associated with the high rates of colorectal cancer among Alaska Native people. The project will enroll 1,000...

This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is providing $505,613 to the Fred Hutchinson Cancer Center in Seattle, WA to develop statistical and computational approaches that leverage genomic data to enable precision cancer prevention strategies. Specifically, the project aims to: (1) create deep learning-based methods to identify tumor subtypes linked to adverse outcomes and assess how...

The National Cancer Institute (NCI) awarded a $439,367 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical Center (UNMC) Division. The grant, titled "Assessment of Strategies for Targeting Transcriptional Co-Activators in Colorectal Cancer," aims to investigate the role of PGC-1 family proteins, specifically PGC-1B, in promoting the survival of colorectal...